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Translational Relevance 
Patients with similar tumor types frequently respond differently to the same therapy. An early 
assessment of treatment response in individual patients would allow rapid selection of the most 
effective treatment. Therapy response in the clinic currently relies on measurements of tumor 
size, which is ineffectual as an early response marker. In response, a number of positron 
emission tomography (PET) and single photon emission computed tomography (SPECT) 
radiotracers have been developed to noninvasively measure therapy-induced cell death a range of 
human cancers. Despite early promise, none of these imaging agents have made it into routine 
clinical practice. The development of new radiotracers to assess response to therapy are required 
if the goal of personalized medicine for the treatment of cancer is to be realized. Here, we 
designed a novel caspase 3-triggered cyclization and nanoaggregation radiotracer with improved 
sensitivity for the detection of cell death in comparison to current imaging gold standards.  
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ABSTRACT 
Purpose: An early readout of tumor response to therapy through measurement of drug or 
radiation-induced cell death may provide important prognostic indications and improved patient 
management. It has been shown that the uptake of 18F-C-SNAT can be used to detect early 
response to therapy in tumors by positron emission tomography via a mechanism of caspase 3-
triggered nanoaggregation.  
Experimental Design: Here, we compared the preclinical utility of 18F-C-SNAT for the 
detection of drug-induced cell death to clinically evaluated radiotracers, 18F-FDG, 99mTc-
Annexin V and 18F-ML-10 in tumor cells in culture, and in tumor-bearing mice in vivo. 
Results: In drug-treated lymphoma cells, 18F-FDG, 99mTc-Annexin V and 18F-C-SNAT cell-
associated radioactivity correlated well to levels of cell death (R2 > 0.8; P < 0.001), with no 
correlation measured for 18F-ML-10 (R2 = 0.05; P > 0.05). A similar pattern of response was 
observed in two human NSCLC cell lines following carboplatin treatment. EL-4 tumor uptake of 
99mTc-Annexin V and 18F-C-SNAT were increased 1.4- and 2.1-fold, respectively in drug-treated 
versus naïve control animals (P < 0.05), although 99mTc-Annexin V binding did not correlate to 
ex vivo TUNEL staining of tissue sections. A differential response was not observed with either 
18F-FDG or 18F-ML-10.  
Conclusions: We have demonstrated here that 18F-C-SNAT can sensitively detect drug-induced 
cell death in murine lymphoma and human NSCLC. Despite favorable image contrast obtained 
with 18F-C-SNAT, the development of next generation derivatives, using the same novel and 
promising uptake mechanism, but displaying improved biodistribution profiles, are warranted for 
maximum clinical utility. 
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INTRODUCTION 
The early assessment of drug-induced tumor cell death is of great prognostic value – enabling 
rapid selection of the most efficacious treatment using a personalized medicine approach. In the 
clinic, current methods to detect response rely on measuring changes in tumor size under the 
guidelines of the response evaluation criteria in solid tumors (RECIST) (1). This approach, 
however, lacks sensitivity, and many weeks may elapse before there is evidence on imaging of 
tumor volume shrinkage.  
 
Cell death, through apoptotic, necrotic or alternate pathways (3), is the surrogate endpoint for 
most anticancer therapies and treatments (4, 5). Given the inadequacy of current techniques for 
monitoring drug response, there have been considerable efforts to develop new techniques to 
detect and image treatment efficacy through measurements of tumor cell death (recently 
reviewed in (6)). As drug-induced cell death manifests itself in many different forms, numerous 
divergent imaging strategies have been employed, targeting a range of both direct and indirect 
biomarkers. Direct imaging biomarkers include caspase 3, whose activation commits the cell to 
programmed (apoptotic) cell death (7, 8), and plasma membrane depolarization (9, 10), which 
occurs downstream of caspase 3 (11) or is exposed as a result of membrane rupture during 
necrosis (9). Indirect methods include measurements of cell metabolism (12, 13), the release of 
enzymes from intracellular compartments (14, 15), or the increased diffusion of water that results 
from loss of cellularity (16).  
 
Radiotracer imaging techniques have shown great promise for the non-invasive detection of cell 
death. Early alterations in glucose metabolism following therapy, characteristic of both stressed 
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and dying cells, have been detected by 2-18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron 
emission tomography (PET) in a range of tumor types (17-20). Furthermore, a draft framework 
has been proposed for the routine use of 18F-FDG-PET for response-assessment in the clinic 
(21). In addition to 18F-FDG, the small molecule radiotracer 2-(5-fluoropentyl)-2-methyl malonic 
acid (18F-ML-10) has shown utility for cell death imaging pre-clinically (22, 23), with first-in-
man trials recently reported (24). Out of all the currently available cell death imaging probes, 
99mTc-HYNIC-labelled Annexin V (99mTc-Annexin V) has been the most widely studied, having 
been used to image drug-induced cell death in human head and neck squamous cell carcinoma 
(25) and tumors of the breast, lymphoma and lung (26). 99mTc-Annexin V binds to 
phosphatidylserine (PS), a temporally-stable biomarker exposed following either apoptotic or 
necrotic cell death. 99mTc-Annexin V, however, has failed to progress beyond phase II/III clinical 
trials due to its poor biodistribution profile (27).  
 
Despite the promise of non-invasive imaging techniques for the assessment of tumor cell death, 
no imaging agent has yet been accepted into routine clinical practice. This has prompted the 
development of a new generation of agents designed to monitor response. One such radiotracer, 
18F-C-SNAT, has been shown in preliminary studies to detect early response to therapy in tumors 
by PET via a novel mechanism of caspase 3-triggered cyclization and nanoaggregation ((8); 
Supplemental Fig. S1). Here, we directly compared the performance of 18F-C-SNAT to 
established radiotracers, 18F-FDG, 99mTc-Annexin V and 18F-ML-10 (Fig. 1), for the non-
invasive detection of cell death. We found that all radiotracers except 18F-ML-10 were able to 
sensitively measure drug-induced cell death in cell culture. However, only 18F-C-SNAT was able 
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to measure treatment response in vivo. Together, our analysis suggests that 18F-C-SNAT may 
have utility for the detection of drug-induced cell death in the clinic.  
 
MATERIALS AND METHODS 
 
Cell culture 
EL-4 murine lymphoma cells and PC-9 human NSCLC (ATCC) were grown in complete RPMI 
medium (Life Technologies; 11.1 mM glucose), supplemented with 10% fetal calf serum, 100 
U/mL penicillin, and 100 μg/mL streptomycin. A549 cells (ATCC) were grown in DMEM 
medium (Life Technologies; 25 mM glucose) with 10% fetal calf serum, 100 U/mL penicillin, 
and 100 μg/mL streptomycin. All cells were propagated at 37°C in a humidified atmosphere 
containing 5% CO2. EL-4 cells could not be authenticated as they were of non-human origin, 
with A549 and PC-9 cells purchased from an authenticated cell biobank just prior to publication. 
 
Radiotracers 
Radiosynthesis of 18F-FDG, 99mTc-Annexin V, 18F-ML-10 and 18F-C-SNAT was based on 
previously described methodology, as detailed in the supplemental materials.  
 
Cell uptake studies 
18 – 20h post either etoposide (Sigma-Aldrich; 15 µM) or vehicle treatment (DMSO), EL-4 cells 
were split into two fractions for analysis: 1. Assessment of radiotracer cell uptake and binding. 2. 
Cell death determination by flow cytometry. For cell uptake studies, 106 EL-4 cells were 
incubated for 10, 30 or 60 min in fresh RPMI (1 mL) at 37 °C with respective radiotracer to 
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determine uptake kinetics. PC-9 and A549 cells were seeded at 105 cells/well of a 6-well plate 
24h prior to carboplatin treatment (Sagent; 200 µM; 72h), as previously described (28). For all 
cell uptake experiments, the radiotracers were added at the following concentrations and specific 
activities: 18F-FDG, 0.185 MBq/mL, <0.38 ± 0.08 µM, >2.6 GBq/µmol; 99mTc-Annexin V, 10 
nM, ~0.185 MBq/mL, 21.1  2.2 GBq/µmol; 18F-ML-10, 1.48 MBq/mL, <0.18 µM, >7.4 
GBq/µmol; 18F-C-SNAT, 1.48 MBq/mL, 0.015 ± 0.007 µM, 123.2 ± 61.4 GBq/µmol. Following 
incubation for the allotted time, adherent cells were trypsinized (0.25% trypsin; 1 mM EDTA) 
and harvested by centrifugation (1200 g; 3 min; 4°C). Detached cells present in the media before 
trypsinization were retained and pooled with the trypsinized cells. Suspension cells were 
collected by centrifugation (1200g; 3 min; 4°C), and all cells were washed three times with ice-
cold Hank’s Buffered Salt Solution (HBSS; 1 mL; 1200 g; 3 min; 4°C), with the final cell pellet 
lysed in 200 µL RIPA buffer (Thermo Fisher Scientific Inc). 100 µL cell lysates were transferred 
to counting tubes and decay-corrected radioactivity was determined on a gamma counter (Cobra 
II Auto-Gamma counter, Packard Biosciences Co). The remaining lysate was frozen and used for 
protein determination following radioactive decay using a bicinchoninic acid (BCA) 96-well 
plate assay (Thermo Fisher Scientific Inc.). 10 µL standards from the original non-washed 
cell/media suspension were counted to quantitate the percentage of radiotracer uptake/binding in 
cells.   
 
To correlate cell-associated radioactivity with levels of drug-induced cell death, mixtures of 
vehicle and etoposide-treated EL-4 cells were prepared 18 – 20h post either vehicle or drug 
addition. Mixtures contained 0%, 25%, 50%, 75% and 100% v/v etoposide-treated cells in 6 mL 
total volume, with the remaining volume made from vehicle-treated cell suspension. One million 
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cells were subsequently collected for cell death analysis by flow cytometry, with the remaining 
cells used to assess cell-associated radioactivity 60 min post radiotracer addition, as described 
above. 
 
Detection of Cell Death In Vitro 
Apoptosis and necrosis in cell mixtures containing 0 – 100% drug-treated cells were visualized 
by flow cytometry using a method adapted from (13), in parallel to cell uptake studies. 
Fluorescein isothiocyanate (FITC)-Annexin V (BioLegend) in combination with 7-amino-
antinomycin D (7-AAD; BioLegend) were used for cell death determination. Early apoptotic 
cells were defined as cells positively stained for FITC-Annexin V but not 7-AAD, with both late 
apoptotic and necrotic classified as cells positive for both stains. FlowJo (v.7.6.5, Tree Star, Inc.) 
was used for analysis. 
 
In vivo tumor models 
All experimental procedures involving animals were approved by Stanford University 
Institutional Animal Care and Use Committee. EL-4 tumor cells (5 × 106 in 100 µL PBS) were 
injected subcutaneously on the back of female C57BL/6 mice (aged 6 – 8 weeks; Charles River 
Laboratories) and grown to ~150 mm3, over ~6 days. Tumor dimensions were measured daily 
using a caliper, with tumor volumes calculated by the equation: volume = (π / 6) × a × b × c, 
where a, b, and c represent three orthogonal axes of the tumor (28). At day 6, animals were size-
matched and either treated with clinically-formulated etoposide (Topsar, Novaplus; 70 mg.kg-1) 
or left untreated. Treatment-response analysis was performed 24h post drug treatment, 7 days 
post tumor cell implantation. In a separate cohort of mice, the effect of drug-treatment on tumor 
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volume was followed up to 96h post therapy. For all other experiments, animals were culled 
25.5h post therapy and tissues excised for analysis.  
 
Imaging studies 
PET imaging scans were carried out on a docked Siemens Inveon PET/CT scanner (matrix size, 
128 × 128 × 159; CT attenuation-corrected; non-scatter corrected), following a bolus 
i.v. injection of ~10 MBq of the radiotracer into tumor-bearing mice (n = 3 – 4 per group). 
Dynamic scans were acquired in list mode format over 90 min, as described in detail in the 
supplemental materials.  
 
Biodistribution studies 
~10 MBq of radiotracer was injected via the tail vein of anaesthetized EL4 tumor-bearing 
C57BL/6 mice (n = 4 – 8 per group). These mice were maintained under anesthesia and warmed 
to 37°C to replicate imaging conditions. At 90 min post radiotracer injection, animals were 
sacrificed by exsanguination via cardiac puncture. For all animals, tumors were excised 
immediately upon death, weighed and rapidly placed in 10% formalin (Fisher Scientific) for 
fixation. Tumor and tissue radioactivity was subsequently determined on a gamma counter 
(decay-corrected; Cobra II Auto-Gamma counter, Packard Biosciences Co). Predefined 3.7 MBq 
standards (250 µL) were also counted for data normalization to injected dose. Data were 
expressed as percent injected dose per gram of tissue (%ID/g). 
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Immunohistochemistry 
Formalin-fixed tumors were embedded in paraffin, sectioned into 5 µm-thick slices and placed 
on microscope slides according to standard procedures (Histo-Tec Laboratory). Sections were 
taken at regular intervals across the entire tumor volume in order to capture previously described 
heterogeneity of EL-4 tumors (29). Sections were stained with either hematoxylin and eosin 
(H&E; Histo-Tec) with a colorimetric TdT-mediated dUTP Nick-End Labeling (TUNEL) assay 
using a kit by Promega (DeadEnd™), according to the manufacturer’s instructions and each 
section digitized using a NanoZoomer 2.0RS whole-slide scanner (Hamamatsu). The percentage 
are of TUNEL-positive cells was measured across the entire tumor section using ImageJ (v.1.47; 
National Institutes of Health). 6 sections were analyzed per tumor, with 3 tumors evaluated per 
treatment group (naïve or drug-treated) for each radiotracer studied. TUNEL positivity was 
compared to the corresponding tumor uptake values previously determined by biodistribution. 
 
Statistical analysis 
Data were expressed as mean ± SD, with the exception of tumor volume measurements, which 
were presented as mean ± SEM. Statistical significance was determined using the Student t test 
(Microsoft Excel). For correlation analysis, linear regression, statistical significance and 95% 
confidence levels were determined using Prism software for Mac OS X (v.6.0e; GraphPad 
Software). Differences between groups were considered significant if P ≤ 0.05. 
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RESULTS 
Measurements in cells 
Time course of radiotracer accumulation 
EL-4 murine lymphoma cells rapidly undergo caspase 3-mediated cell death following etoposide 
treatment (13). By 18h post therapy, cell death had reached 48.9 ± 6.7% in comparison to 2.6 ± 
1.4% in vehicle-treated cells, as determined by flow cytometry (Fig. 2A; P < 0.001; n = 4). 
Temporal 18F-FDG, 99mTc-Annexin V, 18F-ML-10 and 18F-C-SNAT uptake/cell binding was 
measured at 18 – 20h post drug treatment to permit the comparison of their uptake kinetics (Fig. 
2B). 18F-FDG cell uptake increased linearly with time in vehicle-treated cells, rising from 3.1 ± 
1.2% radioactivity/mg protein at 10 min post radiotracer addition, to 10.7 ± 2.2% 
radioactivity/mg protein by 60 min. In comparison, 18F-FDG uptake in drug-treated cells at 60 
min was 2.0 ± 0.7% radioactivity/mg protein, 5.3-fold lower than vehicle controls (n = 4; P = 
0.0008). Conversely, high 99mTc-Annexin V binding to drug-treated cells was evident by just 10 
min post radiotracer addition, at 110.4 ± 4.0% radioactivity/mg protein, with significantly lower 
binding measured in vehicle controls (6.0 ± 1.9% radioactivity/mg protein; P < 0.001; n = 3). By 
60 min post radiotracer addition, 99mTc-Annexin V binding was 24.3-fold higher in drug-treated 
versus vehicle-control cells, at 173.2 ± 15.7% radioactivity/mg and 7.1 ± 2.4% radioactivity/mg, 
respectively (P < 0.001; n = 3). No difference in EL-4 cell uptake in treated versus control cells 
was detectable with 18F-ML-10 over the 60 min time course (P > 0.05; n = 3). Cell-associated 
radioactivity at 60 min in etoposide-treated cells was 3-orders of magnitude lower than 99mTc-
Annexin V, at 0.10 ± 0.04% radioactivity/mg. 18F-C-SNAT retention in drug-treated cells 
followed an initial phase of slow uptake for the initial 30 min, followed by a rapid increase in the 
rate of retention over the proceeding 30 min. There was no change in 18F-C-SNAT cell uptake in 
vehicle control cells over the 60 min time course. At 60 min, 18F-C-SNAT cell uptake was 4.5-
10 
fold higher in drug-treated cell in comparison to vehicle controls, at 1.5 ± 0.2% radioactivity/mg 
and 0.3 ± 0.1% radioactivity/mg, respectively (P < 0.001; n = 3). 
 
Correlation to cell death 
Radiotracer uptake and EL-4 cell binding were further compared to levels of drug-induced cell 
death in culture. Here, different ratios of drug-to-vehicle treated cells were combined to create a 
large dynamic range of dying cells, from ~3–80% of the total cell population (Fig. 3). As both 
early and late apoptotic/necrotic cells were present in the drug-treated samples used to prepare 
the sample series (Supplementary Fig. S2), it was impossible to determine the contribution of 
each mechanism of death to cell uptake using this method. Instead, cell-associated radioactivity 
was compared to cells identified as positively stained by FITC-Annexin V, defined here as 
‘dying cells’. Both 99mTc-Annexin V and 18F-C-SNAT cell uptake/binding significantly 
correlated with levels of cell death (R2 = 0.985 and 0.924, respectively; P < 0.001), with 18F-
FDG uptake negatively correlated to death (R2 = 0.842; P < 0.001). There was no statistically 
significant correlation found for 18F-ML-10 (R2 = 0.053; P > 0.05). It is important to note that 
99mTc-Annexin V was correlated to a fluorescent Annexin V derivative used for the assessment 
of cell death; a potential limitation of this comparison.  
 
Monitoring therapy response in NSCLC 
To explore whether the radiotracer uptake results in EL-4 lymphoma cells were generalizable to 
other tumor cell lines taken from solid tumors, we next assessed radiotracer uptake in either 
vehicle or carboplatin-treated human PC-9 and A549 NSCLC cells; a tumor type well known for 
its relative resistance to common chemotherapeutics (30). 72h carboplatin treatment induced 
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extensive cell death in both lines (Supplementary Fig. S3A). In PC-9 and A549 cells, drug 
treatment resulted in a significant 69.8% (P < 0.001; n = 3) and 43.9% (P = 0.01; n = 3) 
reduction in 18F-FDG uptake 60 min post radiotracer addition (Supplementary Fig. S3B). For 
99mTc-Annexin V, radioactivity was increased 5- and 4-fold in PC-9 and A549 cells, respectively 
in comparison with vehicle control cells (P < 0.001; n = 3). Similarly, 18F-C-SNAT was 
increased 3.8-fold (P = 0.03) and 2.9-fold (P < 0.001) in PC-9 and A549, respectively (n = 3).  
For 18F-ML-10, no significant increase observed in drug-treated cells versus vehicle for either 
PC-9 or A549 cells, in agreement with data obtained for EL-4 cells.    
 
Monitoring treatment response in tumors 
We next evaluated the specificity of each radiotracer to non-invasively measure tumor cell death 
in vivo. Subcutaneous EL-4 tumors grew rapidly in C57BL/6 mice, detectably by day 4 and 
reaching ~150 mm3 six days post-implantation (Fig. 4A). On day 6 mice were size matched and 
either treated with drug or left untreated. Drug treatment resulted in a significant 40% reduction 
in tumor volume after 24h, reduced from 159.8 ± 26.3 mm3 to 95.3 ± 16.0 mm3, whereas the 
tumor volume increased from 145.3 ± 23.2 mm3 to 256.4 ± 36.3 mm3 in naïve animals (80% 
increase; P < 0.001; n = 7/group). At this time point, drug-treated tumors were characterized by 
loss of tumor cellularity, immune cell infiltration (Fig. 4B) and extensive DNA damage 
throughout multiple slices of the tumor, determined by histochemical staining (Fig. 4C). In naïve 
tumor-bearing animals, DNA damage was limited to the peripheral margins of the tumor. By 96h 
post therapy, tumors had shrunk to 42.8 ± 7.2 mm3, growing to 393.4 ± 23.2 mm3 in naïve 
animals (Fig. 4A).  
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Tumor uptake and radiotracer biodistribution 
18F-FDG, 99mTc-Annexin V, 18F-ML-10 and 18F-C-SNAT tumor uptake, illustrated in Figure 4D, 
and ex vivo biodistribution profiles, summarized in Supplemental Table 1, were measured in EL-
4 tumor-bearing animals 90 min post radiotracer injection in either drug-treated or naïve animals. 
18F-FDG, 99mTc-Annexin V and 18F-ML-10 pharmacokinetics were dominated by renal 
excretion. In addition, high heart and kidney retention were measured with 18F-FDG and 99mTc-
Annexin V, respectively. 18F-C-SNAT elimination was through both the renal and hepatobiliary 
routes. 18F-ML-10 radioactivity had almost completely cleared from all organs by 90 min. For 
drug-treated mice, 18F-FDG was significantly higher than naïve animals in liver, small intestine 
and large intestine, but lower in muscle (P < 0.05). Bone-associated radioactivity was 
significantly higher in treated versus naïve animals with 99mTc-Annexin V (P < 0.05). 
 
Ex vivo γ-counting of excised tumors revealed a significant increase in tumor-associated 
radioactivity in drug-treated versus naïve tumor-bearing mice for both 99mTc-Annexin V and 18F-
C-SNAT, at 1.4- and 2.1-fold, respectively (P < 0.05; n = 4 – 7 mice/group). There was no 
change in 18F-FDG or 18F-ML-10 tumor uptake and retention following drug treatment 90 min 
post injection of radiotracer (Fig. 4D and Supplemental Table 1). A positive tumor-to-muscle 
ratio was measured with all radiotracers and treatment conditions, whereas a positive tumor-to-
blood ratio was only measured with 18F-FDG at 90 min post-radiotracer injection (Supplemental 
Table 2). 
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Correlation of radiotracer binding to histology  
The specificity of the radiotracers to image tumor response to therapy was achieved through 
correlation of their retention with TUNEL staining, an independent marker of drug efficacy and 
the current clinical gold standard (Fig. 5). EL-4-tumor bearing animals injected with 18F-C-
SNAT showed a good correlation (R2 = 0.778; n = 3 animals/group; P = 0.02) between whole 
tumor mean radioactivity at 90 min post radiotracer injection and TUNEL staining in histological 
sections obtained post mortem, whereas there was no correlation for either 18F-FDG, 99mTc-
Annexin V or 18F-ML-10 (R2 = 0.249, 0.231 and 0.001, respectively; n = 3 animals/group; P > 
0.05).   
 
Radionuclide imaging of tumor cell death 
Dynamic PET images were acquired from animals with implanted EL-4 tumors (Fig. 6). 
Similarly to ex vivo biodistribution data, 18F-FDG distribution was characterized by high uptake 
in the tumor, heart and bladder (Fig. 6A). 18F-FDG-PET/CT fusion images, highlighting the 
tumor xenograft and rendered in 3D, are shown in Figure 6A(ii) (full, uncropped versions are 
displayed in Supplementary videos M1 and M2). 18F-FDG tumor uptake was characterized by a 
steady increase in tumor retention in both naïve and drug-treated animals, with a plateauing of 
radioactivity recorded between 60 – 90 min. By 90 min a significant increase in tumor-associated 
18F-FDG uptake was measured in drug-treated animals in comparison to naïve animals at 15.1 ± 
1.2 %ID/g and 12.3 ± 1.1 %ID/g, respectively (P = 0.011; n = 4/group). There was no difference 
in the area under the tumor time-activity curves (AUC) between the two treatment groups (P > 
0.05).  
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Tumor uptake and retention was visible above background in both naïve and drug-treated 
animals with 18F-ML-10 PET (Fig. 6B), with increased uptake noticeable around the periphery of 
the tumor (Fig. 6B(ii), Supplemental videos M3 and M4). The kinetic profile of tumor retention 
varied considerably for 18F-ML-10 in comparison to 18F-FDG, as shown by the tumor time-
activity curves (TAC). Rapid tumor uptake of 18F-ML-10, peaking at 10 minutes, preceded a 
slow washout of radioactivity over the remaining 80 minutes. There was no difference in image-
derived tumor uptake values (%ID/g90 or AUC) between naïve and drug-treated cohorts. 
 
In contrast to what was observed with 18F-ML-10 and 18F-FDG-PET, a clear difference in tumor-
associated 18F-C-SNAT uptake between treatment groups was measured by PET (Fig. 6C). In 
drug-treated mice, background activity was increased when compared to naïve mice, possibly 
reflecting the trend towards increased blood retention observed in biodistribution studies 
(Supplemental Table 1). In naïve mice, tumor uptake was confined to the margins (Fig. 6C(ii) 
and Supplemental video M5), corresponding to elevated regions of DNA damage observed by 
histochemical staining of excised tumors (Fig. 4C), whereas uniform tumor distribution was 
evident in tumors of drug-treated mice (Fig. 6C(ii) and Supplemental video M6). The profile of 
tumor uptake varied considerably between drug-treated and naïve animals (Fig. 6C(iii)). In drug-
treated animals, C-SNAT rapidly accumulated in tumors, peaking at 10 minutes, with subsequent 
stabilization of tumor-associated radioactivity. For naïve animals, 18F-C-SNAT peaked to similar 
levels 10 minutes post injection, followed by a slow washout from the tumor over the remaining 
80 minutes. By 90 min post injection, tumor uptake was 2.2 ± 0.2 %ID/g in drug-treated tumors 
versus 0.8 ± 0.2 %ID/g when left untreated, a 2.7-fold increase (P < 0.001, n = 3-4 
animals/group).  
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Dynamic SPECT imaging was not possible with the experimental setup available. Instead, static 
60 – 90 min SPECT images were obtained for 99mTc-Annexin V (Supplemental Fig. S4). These 
images revealed typical 99mTc-Annexin V tissue distribution, with high liver, kidney and bladder 
radioactivity, which was consistent with biodistribution data. Although tumor uptake was evident 
above background, we were unable to distinguish between drug-treated tumors and naïve 
controls using qualitative imaging data alone, reflecting the small differences observed by ex 
vivo γ-counting. 
 
 
DISCUSSION 
Resistance to chemotherapy and molecularly-targeted therapies provides a major hurdle for 
cancer treatment due to the underlying genetic and biochemical heterogeneity of tumors. An 
early read-out of drug efficacy, through the measurement of tumor cell death, would provide 
valuable insights into resistance status, allowing the selection of the most appropriate therapy (or 
combination) for the individual and termination of ineffectual treatments at an early stage.  
 
There have been considerable efforts to develop methods to non-invasively measure tumor cell 
death (recently reviewed in (6)), but as yet, no cell-death imaging agent has made it into routine 
clinical practice. There is therefore a need to develop new imaging agents for the assessment of 
therapy response. A number of important considerations are required to assess the suitability for 
any novel cancer imaging agent: namely, the temporal and spatial distribution of the imaging 
biomarker in tumors, the sensitivity and specificity of detection, tumor-to-background contrast 
and the pharmacokinetic profile of the radiotracer. Here, we systematically compared the novel 
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imaging agent, 18F-C-SNAT, to clinically evaluated radiotracers, 18F-FDG, 18F-ML-10 and 
99mTc-Annexin V, for the detection of tumor cell death. We selected the well-characterized EL-4 
murine lymphoma model (12-14) for the assessment of drug-induced cell death. Lymphomas 
typically respond well to first-line therapy in comparison to the majority of solid tumor types 
(31), accurately reflected by extensive drug-induced cell death observed here in EL-4 cells and in 
implanted tumors (Fig. 2A and 4A – C, respectively). We then further assessed therapy response 
in two additional NSCLC lines to confirm that the variability in results between the different 
radiotracers was not specific to this one cell line. 
 
In cell culture experiments, EL-4 cell-associated radioactivity for the different radiotracers varied 
over 3 orders of magnitude following drug treatment (Fig. 2), highlighting large differences in 
their sensitivity and mechanisms to detect cell death. For 99mTc-Annexin V, cell-associated 
radioactivity was 173.2 ± 15.7% radioactivity/mg protein at 60 min post addition of radiotracer, 
in comparison to just 0.10 ± 0.04% radioactivity/mg for 18F-ML-10. Furthermore, 18F-ML-10 
uptake failed to correlate to drug-induced cell death in this model, either in cells or in tumors 
(Fig. 3 and 5, respectively); a pattern also replicated in the two NSCLC cells tested here. This is 
in contrast to previous reports in a preclinical model of neuronal cell death (27) and in drug-
treated tumor cells in culture, in which a tritiated derivative of ML-10 was used (32). It is 
possible that tissue culture media buffering of extracellular pH may reduce cell binding of 18F-
ML-10, whose binding is purportedly mediated through the acidification of the external plasma 
membrane leaflet (32). Experimental evidence linking apoptosis-specific alterations in 
asymmetric membrane distribution to 18F-ML-10 uptake is limited however, and not supported 
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by our findings in vivo, where the acidic tumor microenvironment likely remains largely un-
buffered (14).  
 
Drug treatment induced high levels of DNA damage and loss of cellularity in vivo, characteristic 
of an apoptotic response. Despite the high levels of cell death, accumulation in EL-4 tumors was 
moderate (<3 %ID/g) for all radiotracers except 18F-FDG (Fig 4C and 6A). A significant 
decrease in 18F-FDG uptake is indicative of a positive response to therapy, as measured here in 
EL-4 cells (Fig 2B and 3), as a consequence of glucose transporter redistribution from the plasma 
membrane to the cytosol (13). Despite levels of drug-induced cell death correlating excellently 
with a reduction in 18F-FDG uptake in cells, no response was detectable by γ-counting of excised 
tumors ex vivo (Fig. 4D and 5), with a small but statistically significant increase observed by 
semi-quantitative imaging parameters in vivo. 18F-FDG uptake is not confined to tumor cells, 
with drug-induced alterations in other constituents of the tumor microenvironment potentially 
confounding measurements in vivo. For example, infiltration of FDG-avid immune cells 
following drug treatment, detected here by H&E staining (Fig. 4B), may mask tumor cell-
specific reductions in glucose metabolism in this immuno-competent murine model, as has been 
observed elsewhere (33, 34). These data are in line with the general advice for nuclear medicine 
physicians to wait a minimum of 10 days after chemotherapy before performing 18F-FDG-PET 
scans to bypass potential immune effects (21). A reduction in 18F-FDG in lymphoma patients has 
however been observed just 24h post initiation of treatment (35) highlighting a potential 
limitation of preclinical mouse models of cancer, where the nature and timing of immune 
responses are known not to precisely match those found in the clinic (36). 
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While changes in 18F-FDG uptake act as an indirect measure of treatment response, Annexin V 
and its labeled derivatives have been shown to measure bona fide cell death, through binding to 
exposed PS with nanomolar affinity (37). Annexin V continues to be the gold standard for 
measurements of cell death in vitro. In culture, 99mTc-Annexin V binding excellently correlated 
to cell death, with high sensitivity and specificity in both the lymphoma and two NSCLC cell 
lines. Despite encouraging performance in cell culture, a poor pharmacokinetic profile and low 
tumor binding was observed in vivo. The half-life of 99mTc (6 h) permits imaging at time points 
over 12h post radiotracer injection. The rapid clearance of 99mTc-Annexin V from circulation and 
absence of tissue redistribution just 30 min post injection (38) however supports an imaging 
protocol whereby response is assessed at 90 min post-intravenous injection. At this time point, 
99mTc-Annexin V tumor uptake did not correlate significantly to levels of DNA damage (Fig. 5), 
with a modest 40% increase in radioactivity accumulation following drug treatment detectable by 
average counts in excised tumors. Non-specific tumor retention of Annexin V in the vascular 
space has recently been attributed to changes in enhanced permeability and retention (EPR) 
effects at baseline and post therapy (39). Despite advances in both site-specific and PET labeling 
strategies little has been achieved to improve the in vivo profile and tumor binding of this 
radiotracer (40).  
 
Given the relatively poor performance of existing radiotracers, alternative approaches are 
required for the measurement of cell death. PET-labeled and fluorescent derivatives of a peptidic 
caspase 3/7 substrate, C-SNAT and C-SANF, respectively, have recently emerged as promising 
agents for cell death imaging (8, 41). Specificity of C-SNAT for caspase 3/7 was previously 
shown, through abrogation of signal in the presence of a caspase 3 inhibitor, and with a control 
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probe containing the D-DEVD sequence, resistant to caspase 3 cleavage (8, 41). Here, 18F-C-
SNAT uptake was significantly elevated between 2.9- and 4.5-fold in EL-4 and NSCLC cells 
following treatment. In EL-4 xenograft tumors, 18F-C-SNAT uptake correlated strongly with the 
levels of drug-induced DNA damage (R2 = 0.778), with 18F-C-SNAT uptake increased 2.7-fold 
in drug-treated tumors versus naïve controls just 24h post therapy. This early readout of 
treatment response was shown to be an accurate predictor of outcome, assessed by almost 
complete tumor regression 72h post therapy (Fig. 4A). At 90 min post radiotracer injection, 
washout of unbound radiotracer in muscle resulted in a positive tumor-to-muscle ratio in both 
drug-treated and naïve mice. Retention of the radiotracer in the blood pool combined with 
relatively low tumor uptake however reduced tumor-to-background contrast and may confound 
simple endpoint measurements, particularly for the evaluation of vascular-damaging anticancer 
agents where radiotracer delivery to the tumor may be impaired. Of note was the combined 
hepatobiliary and renal excretion of 18F-C-SNAT, which may limit assessment of treatment 
response to tumors of the upper thoracic region, for example, those of the breast, in which 
background is minimal. We are currently developing second-generation caspase 3-mediated 
nanoaggregation radiotracers with improved pharmacokinetic properties, and improved signal to 
background for enhanced clinical utility. 
 
Not included in this comparison study was the PET-labeled caspase 3 inhibitor, isatin-5-
sulfonamide (18F-ICMT-11), which has shown potential for tumor cell death imaging (7, 28, 42) 
and has recently progressed to clinical trials (43). Under similar conditions to those described 
here however, EL-4 tumor retention of 18F-ICMT-11 was increased by a modest 65% in treated 
versus vehicle control tumors (44), whilst sharing the same suboptimal pharmacokinetic profile 
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as 18F-C-SNAT, and displaying lower tumor binding in vivo (42). A potential limitation of 
caspase 3-based imaging agents, such as 18F-C-SNAT and 18F-ICMT-11, is the transient 
temporal expression of cleaved caspase 3 following the induction of apoptosis. As a result, the 
imaging window for the detection of treatment response must be carefully selected for these 
caspase 3-based imaging agents (42). In addition, measurements of caspase 3 limits detection to 
apoptotic mechanisms of death and fails to detect therapy-induced necrosis (28). 
 
In summary, we have systematically compared a range of radionuclide imaging agents, with 
diverse mechanisms of action, for cell death imaging. Despite promising results obtained in 
isolated adherent and suspension cells in culture, confounding factors in vivo, such as 
microenvironmental changes and radiotracer biodistribution, limited the ability of both 99mTc-
Annexin V and 18F-FDG to sensitively measure cell death. The claimed selectivity of 18F-ML-10 
to monitor treatment response could not be replicated in the EL-4 tumor model in the current 
work. Whilst progress has been made with the development of novel PET agents, such as 18F-C-
SNAT, there is an urgent need to continue to develop new radiotracers which display an 
improved pharmacokinetic profile and tumor uptake in order to measure treatment response of 
tumors located in the abdomen and surrounding regions. Furthermore, detailed clinical studies 
will be needed to truly identify a radiotracer that can have utility in monitoring treatment 
efficacy. 
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FIGURES 
 
FIGURE 1. Chemical structure and molecular weight for 18F-FDG, 99mTc-Annexin V, 18F-ML-
10 and 18F-C-SNAT. The radioisotope is shown in bold type. 
 
FIGURE 2. Time course of radiotracer uptake and retention in etoposide- and vehicle-treated 
EL-4 cells. (A) Flow cytometric analysis of vehicle or drug-treated (15µM etoposide; 18h) EL-4 
cells. Cell death was detected with FITC-Annexin V (λ Ex/Em = 488/535) and 7-AAD staining 
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(λ Ex/Em = 488/647). Q1 = viable; Q2 = early apoptotic; Q3 = late apoptotic/necrotic. (B) 
Temporal changes in cell-associated radioactivity in 18h vehicle or etoposide-treated cells were 
measured with 18F-FDG, 99mTc-HYNIC-Annexin V, 18F-ML-10 and 18F-C-SNAT. Mean ± SD (n 
= 3-4/group). * P < 0.05, ** P < 0.01, *** P < 0.001. 
 
FIGURE 3. Correlation between therapy-induced cell death and radiotracer accumulation in 
cells. Flow cytometic quantitation of cell death was compared to cell-associated radioactivity for 
18F-FDG, 99mTc-HYNIC-Annexin V, 18F-ML-10 and 18F-C-SNAT in cell mixtures. Lines of 
linear regression and 95% confidence levels (broken gray lines) are shown. Mean ± SD (n = 3 
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independent experiments). Experiments performed on separate days are represented by either 
gray, open, or filled circles. *** P < 0.001; NS, not significant. 
 
FIGURE 4. Characterization of therapy response and correlation to radiotracer accumulation in 
tumors. (A) Caliper measurements of EL-4 tumor volumes in naïve and drug-treated mice. 
Measurements were recorded as a function of time post cell implantation, with mice treated on 
day 6 (red arrow). All subsequent analysis was made on day 7, 24h post therapy (green arrow). 
Data represents mean ± SEM (n = 7-8 mice/group). (B) H&E staining of naïve and drug-treated 
histological tumor sections. Tumor sections were scanned by a whole-slide scanner, with 
representative regions of interest selected at 10× and 20× magnification (insert), indicating loss 
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of cellularity and immune cell infiltration following treatment (day 7, 24h post drug). Scale bar = 
100 µm. (C) DNA fragmentation (colorimetric TUNEL assay) detection in naïve and drug-
treated whole tumor sections. Representative false-color sections are shown, acquired at 1.25× 
magnification (scale bar = 2.5 mm). (D) Radiotracer accumulation in drug-treated and naïve 
tumors. Radioactivity was measured by γ-counting of excised tumors 90 min post radiotracer 
administration. The values are the mean value ± SD of at least 4 mice (number of mice shown on 
graph).  
 
FIGURE 5. Correlation of radiotracer uptake to histological measure of tumor cell death. DNA 
damage, assessed by TUNEL staining of whole tumor sections (n = 6 sections per tumor, 3 
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tumors/treatment group), were compared to tumor-associated 18F-FDG, 99mTc-HYNIC-Annexin 
V, 18F-ML-10 and 18F-C-SNAT radioactivity measured in tumors. Radioactivity was measured 
by γ-counting of excised tumors 90 min post radiotracer administration (n = 3 tumors/group). 
Lines of linear regression and 95% confidence levels (broken gray lines) are shown. * P < 0.05, 
** P < 0.01, *** P < 0.001. 
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FIGURE 6. Dynamic PET imaging of cell death in vivo. PET image analysis of EL-4 tumors in 
naïve and drug-treated mice was performed for 18F-FDG (A), 18F-ML-10 (B) and 18F-C-SNAT 
(C). Corresponding axial and sagittal PET-CT images (60 – 90 min summed activity) of naïve 
and drug-treated EL-4 tumor-bearing mice are shown in panels (i). Arrowheads indicate the 
tumor, identified from the CT image. (ii) Representative PET-CT (60 – 90 min summed activity) 
volume rendering technique (VRT) images of tumor-bearing naïve and drug-treated mice. 
Arrows indicate the tumor. (iii) The tumor time-activity curves (TAC) representing average 
counts from a dynamic 90-minute scan 24h post drug treatment and in naïve animals. Data are 
mean ± SD (n = 3 – 4 animals per group). * P < 0.05, *** P < 0.001. B = bladder, H = heart, L = 
liver, SI = small intestine. 
